Inventor
BORODIC GARY E
US23 patents
⚠️ This page may combine multiple inventors who share the name “BORODIC GARY E”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BORODIC GARY E
10 patentsUS5053005AOct 1, 1991
Chemomodulation of curvature of the juvenile spine
BORODIC GARY E137 citations97
US8926991B2Jan 6, 2015
Botulinum toxin and the treatment of primary disorders of mood and affect
BORODIC GARY E18 citations92
US9066851B2Jun 30, 2015
Extended length botulinum toxin formulation for human or mammalian use
BORODIC GARY E10 citations84
US8679486B2Mar 25, 2014
High-potency botulinum toxin formulations
BORODIC GARY E9 citations84
US8192979B2Jun 5, 2012
Compositions, methods and devices for preparing less painful Botulinum toxin formulations
BORODIC GARY E11 citations79
US7270826B2Sep 18, 2007
Methods of using Botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion)
BORODIC GARY E9 citations73
US11123412B2Sep 21, 2021
Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
BORODIC GARY E0 citations62
US11123411B2Sep 21, 2021
Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
BORODIC GARY E1 citations62
US11096993B2Aug 24, 2021
Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
BORODIC GARY E0 citations52
US9393291B2Jul 19, 2016
Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
BORODIC GARY E1 citations48
REVANCE THERAPEUTICS INC
5 patentsUS9950042B2Apr 24, 2018
Extended length botulinum toxin formulation for human or mammalian use
REVANCE THERAPEUTICS INC4 citations73
US9901627B2Feb 27, 2018
Topical ocular preparation of botulinum toxin for use in ocular surface disease
REVANCE THERAPEUTICS INC5 citations73
US11484580B2Nov 1, 2022
Topical ocular preparation of botulinum toxin for use in ocular surface disease
REVANCE THERAPEUTICS INC0 citations62
US10441641B2Oct 15, 2019
Botulinum toxin and the treatment of primary disorders of mood and affect
REVANCE THERAPEUTICS INC1 citations62
US10857215B2Dec 8, 2020
Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
REVANCE THERAPEUTICS INC0 citations48
ASS SYNAPSE BIOLOG
4 patentsUS5696077ADec 9, 1997
Pharmaceutical composition containing botulinum B complex
ASS SYNAPSE BIOLOG161 citations98
US5183462AFeb 2, 1993
Controlled administration of chemodenervating pharmaceuticals
ASS SYNAPSE BIOLOG167 citations98
US5401243AMar 28, 1995
Controlled administration of chemodenervating pharmaceuticals
ASS SYNAPSE BIOLOG111 citations97
US5298019AMar 29, 1994
Controlled administration of chemodenervating pharmaceuticals
ASS SYNAPSE BIOLOG98 citations95
BOTULINUM TOXIN RES ASS INC
3 patentsUS6429189B1Aug 6, 2002
Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
BOTULINUM TOXIN RES ASS INC107 citations97
US7691394B2Apr 6, 2010
High-potency botulinum toxin formulations
BOTULINUM TOXIN RES ASS INC33 citations92
US7537773B1May 26, 2009
Chemodenervating pharmaceutical as anti-inflammatory agent
BOTULINUM TOXIN RES ASS INC29 citations92